TW202016097A - 布魯頓氏酪胺酸激酶之抑制劑 - Google Patents

布魯頓氏酪胺酸激酶之抑制劑 Download PDF

Info

Publication number
TW202016097A
TW202016097A TW108116422A TW108116422A TW202016097A TW 202016097 A TW202016097 A TW 202016097A TW 108116422 A TW108116422 A TW 108116422A TW 108116422 A TW108116422 A TW 108116422A TW 202016097 A TW202016097 A TW 202016097A
Authority
TW
Taiwan
Prior art keywords
alkyl
methyl
membered
occurrence
group
Prior art date
Application number
TW108116422A
Other languages
English (en)
Chinese (zh)
Inventor
布萊恩 T 哈柏金
馬斌
羅賓 普林斯
以撒 馬克思
喬爾跟 舒茲
馬爾他 內娃連恩
麥可爾 戴瓊史瑞特
Original Assignee
美商百健Ma公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百健Ma公司 filed Critical 美商百健Ma公司
Publication of TW202016097A publication Critical patent/TW202016097A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW108116422A 2018-05-14 2019-05-13 布魯頓氏酪胺酸激酶之抑制劑 TW202016097A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671053P 2018-05-14 2018-05-14
US62/671,053 2018-05-14

Publications (1)

Publication Number Publication Date
TW202016097A true TW202016097A (zh) 2020-05-01

Family

ID=67002348

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108116422A TW202016097A (zh) 2018-05-14 2019-05-13 布魯頓氏酪胺酸激酶之抑制劑

Country Status (9)

Country Link
US (1) US10899753B2 (enExample)
EP (1) EP3793994B1 (enExample)
JP (1) JP7359782B2 (enExample)
AR (1) AR115085A1 (enExample)
ES (1) ES2968222T3 (enExample)
MA (1) MA52629A (enExample)
TW (1) TW202016097A (enExample)
UY (1) UY38233A (enExample)
WO (1) WO2019222101A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11820760B2 (en) * 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
EP4081514A1 (en) * 2019-12-23 2022-11-02 Biogen MA Inc. Btk inhibitors
CN112062691B (zh) * 2020-06-18 2022-12-09 中国农业科学院油料作物研究所 一种柠檬醛苯丁酸肟酯类化合物及其合成方法和应用
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
KR20240128831A (ko) 2021-12-30 2024-08-27 베이진 스위찰랜드 게엠베하 브루톤 티로신 키나아제(btk) 억제제와 e3 리가아제 리간드의 접합에 의한 btk의 분해 및 사용 방법
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
KR20140131955A (ko) 2012-03-09 2014-11-14 카나 바이오사이언스 인코포레이션 신규 트리아진 유도체
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
AU2014362231B2 (en) 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
ES2968222T3 (es) 2024-05-08
AR115085A1 (es) 2020-11-25
MA52629A (fr) 2021-03-24
JP7359782B2 (ja) 2023-10-11
EP3793994B1 (en) 2023-08-23
WO2019222101A1 (en) 2019-11-21
JP2021523206A (ja) 2021-09-02
UY38233A (es) 2019-12-31
US10899753B2 (en) 2021-01-26
US20190382394A1 (en) 2019-12-19
EP3793994A1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
TW202016097A (zh) 布魯頓氏酪胺酸激酶之抑制劑
EP2215049B1 (en) P2x3, receptor antagonists for treatment of pain
EP4051680B1 (en) Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
HK1212984A1 (en) Imidazopyridine compounds
JP5620393B2 (ja) 脳梗塞治療薬
KR20150106895A (ko) Ship1 조절제 및 그와 관련된 방법
JP7597781B2 (ja) 化学化合物
WO2009125853A1 (ja) ホモシステイン合成酵素阻害薬
JP7779900B2 (ja) Btk阻害剤
WO2023086521A1 (en) Btk inhibitors
JP2025094159A (ja) ブルトン型チロシンキナーゼの阻害剤
TWI652265B (zh) 氮雜吲哚衍生物
HK40049019B (en) Inhibiting agents for bruton's tyrosine kinase
HK40049019A (en) Inhibiting agents for bruton's tyrosine kinase
TWI921490B (zh) 哺乳動物slc6a19功能之小分子抑制劑
TW202302575A (zh) 哺乳動物slc6a19功能之小分子抑制劑
WO2026006527A1 (en) Covalent inhibitors of jak2 jh2 domain
CN114450005A (zh) 用于治疗神经障碍的化合物
HK40085749A (en) P2x3 modulators